Prognostic Value of


Journal

Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 06 2020
revised: 20 06 2020
accepted: 24 06 2020
pubmed: 25 7 2020
medline: 15 12 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

Splenic marginal zone lymphoma (SMZL) is an indolent non-Hodgkin lymphoma usually with a good prognosis, but no clear metabolic behavior at fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). The aim of our analysis was to investigate the prognostic role of baseline 18F-FDG PET/CT parameters in SMZL. We retrospectively included 42 patients who received 18F-FDG-PET/CT before any treatments, and PET images were evaluated visually and semi-quantitatively by measuring lesion to liver (L-L) maximum standardized uptake volume (SUVmax) ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume, and total lesion glycolysis. Progression-free (PFS) and overall survival (OS) curves were plotted according to the Kaplan-Meier method. In all patients, an increased splenic FDG uptake (higher than the background) was identified, showing the presence of diffuse spleen uptake in 35 patients and focal uptake in the remaining 7 patients. At a median follow-up of 51 months, relapse or progression of disease occurred in 23 patients with an average time of 38.1 months from the baseline 18F-FDG PET/CT, and death occurred in 4 patients with an average time of 26.8 months. The estimated 2-year PFS and OS rates were 78% and 90%, respectively, whereas 5-year PFS and OS rates were 63% and 82%, respectively. At multivariate analysis, only L-L SUV R and L-BP SUV R were independent prognostic factors for PFS. In addition, no significant association was discovered for OS, considering all features. L-L SUV R and L-BP SUV R were independently correlated with PFS.

Identifiants

pubmed: 32703751
pii: S2152-2650(20)30316-5
doi: 10.1016/j.clml.2020.06.018
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e897-e904

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Domenico Albano (D)

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy. Electronic address: doalba87@libero.it.

Luca Camoni (L)

Nuclear Medicine, Spedali Civili Brescia, Brescia, Italy.

Raffaele Giubbini (R)

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.

Francesco Bertagna (F)

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH